Nicotine increases dopamine transporter function in rat striatum through a trafficking-independent mechanism

European Journal of Pharmacology

Volumn 554, Issue 2-3, 2007, Pages 128-136

  Middleton, Lisa S ^a   Apparsundaram, Subbu ^b   King Pospisil, Kelley A ^b   Dwoskin, Linda P ^a  

^a University of Kentucky   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Dopamine transporter; Nicotine; Trafficking

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; DOPAMINE TRANSPORTER; NICOTINE; SODIUM CHLORIDE; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; BIOTINYLATION; CELL SURFACE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; FRACTIONATION; MALE; NONHUMAN; POTENTIOMETRY; PRIORITY JOURNAL; RAT; RAT STRAIN; SYNAPTOSOME;

ANIMALS; BINDING, COMPETITIVE; BIOLOGICAL TRANSPORT; BLOTTING, WESTERN; CELL MEMBRANE; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GANGLIONIC STIMULANTS; INJECTIONS, SUBCUTANEOUS; KINETICS; MALE; NICOTINE; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; SYNAPTOSOMES; TIME FACTORS; TRITIUM;

EID: 33845346125     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.09.074     Document Type: Article

References (62)

1. Andersson K., Fuxe K., Agnati L.F., and Eneroth P. Effects of acute central and peripheral administration of nicotine on ascending dopamine pathways in the male rat brain. Evidence for nicotine induced increases of dopamine turnover in various telencephalic dopamine nerve terminal systems. Med. Biol. 59 (1981) 170-176
2. Apparsundaram S., Schroeter S., Giovanetti E., and Blakely R.D. Acute regulation of norepinephrine transport: II. PKC-modulated surface expression of human norepinephrine transporter proteins. J. Pharmacol. Exp. Ther. 287 (1998) 744-751
3. Apparsundaram S., Sung U., Price R.D., and Blakely R.D. Trafficking-dependent and-independent pathways of neurotransmitter transporter regulation differentially involving p38 mitogen-activated protein kinase revealed in studies of insulin modulation of norepinephrine transport in SK-N-SH cells. J. Pharmacol. Exp. Ther. 299 (2001) 666-677
4. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
5. Carr L.A., Rowell P.P., and Pierce W.M. Effects of subchronic nicotine administration on central dopaminergic mechanisms in the rat. Neurochem. Res. 14 (1989) 511-515
6. Cass W.A., Zahniser N.R., Flach K.A., and Gerhardt G.A. Clearance of exogenous dopamine in rat dorsal striatum and nucleus accumbens: role of metabolism and effects of locally applied uptake inhibitors. J. Neurochem. 61 (1993) 2269-2278
7. Chi L., and Reith M.E. Substrate-induced trafficking of the dopamine transporter in heterologously expressing cells and in rat striatal synaptosomal preparations. J. Pharmacol. Exp. Ther. 307 (2003) 729-736
8. Ciliax B.J., Heilman C., Demchyshyn L.L., Pristupa Z.B., Ince E., Hersch S.M., Niznik H.B., and Levey A.I. The dopamine transporter: immunochemical characterization and localization in brain. J. Neurosci. 15 (1995) 1714-1723
9. Clarke P.B. Nicotine and smoking: a perspective from animal studies. Psychopharmacology 92 (1987) 135-143
10. Clift-O'Grady L., Linstedt A.D., Lowe A.W., Grote E., and Kelly R.B. Biogenesis of synaptic vesicle-like structures in a pheochromocytoma cell line PC-12. J. Cell Biol. 110 (1990) 1693-1703
11. Copeland B.J., Vogelsberg V., Neff N.H., and Hadjiconstantinou M. Protein kinase C activators decrease dopamine uptake into striatal synaptosomes. J. Pharmacol. Exp. Ther. 277 (1996) 1527-1532
12. Corrigall W.A., Franklin K.B., Coen K.M., and Clarke P.B. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology 107 (1992) 285-289
13. Daws L.C., Callaghan P.D., Moron J.A., Kahlig K.M., Shippenberg T.S., Javitch J.A., and Galli A. Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. Biochem. Biophys. Res. Commun. 290 (2002) 1545-1550
14. Dwoskin L.P., Wilkins L.H., Pauly J.R., and Crooks P.A. Development of a novel class of subtype-selective nicotinic receptor antagonist: pyridine-N-substituted nicotine analogs. Ann. N.Y. Acad. Sci. 868 (1999) 617-619
15. Garcia B.G., Wei Y., Moron J.A., Lin R.Z., Javitch J.A., and Galli A. Akt is essential for insulin modulation of amphetamine-induced human dopamine transporter cell-surface redistribution. Mol. Pharmacol. 68 (2005) 102-109
16. Ghosheh O., Dwoskin L.P., Li W.K., and Crooks P.A. Residence times and half-lives of nicotine metabolites in rat brain after acute peripheral administration of [2′-(14)C]nicotine. Drug Metab. Dispos. 27 (1999) 1448-1455
17. Gnegy M.E., Khoshbouei H., Berg K.A., Javitch J.A., Clarke W.P., Zhang M., and Galli A. Intracellular Ca2+ regulates amphetamine-induced dopamine efflux and currents mediated by the human dopamine transporter. Mol. Pharmacol. 66 (2004) 137-143
18. Hart C., and Ksir C. Nicotine effects on dopamine clearance in rat nucleus accumbens. J. Neurochem. 66 (1996) 216-221
19. Hochstenbach F., David V., Watkins S., and Brenner M.B. Endoplasmic reticulum resident protein of 90 kilodaltons associates with the T- and B-cell antigen receptors and major histocompatibility complex antigens during their assembly. Proc. Natl. Acad. Sci. 89 (1992) 4734-4738
20. Holton K.L., Loder M.K., and Melikian H.E. Nonclassical, distinct endocytic signals dictate constitutive and PKC-regulated neurotransmitter transporter internalization. Nat. Neurosci. 8 (2005) 881-888
21. Horn A.S. Dopamine uptake: a review of progress in the last decade. Prog. Neurobiol. 34 (1990) 387-400
22. Hu M., Liu Q.S., Chang K.T., and Berg D.K. Nicotinic regulation of CREB activation in hippocampal neurons by glutamatergic and nonglutamatergic pathways. Mol. Cell. Neurosci. 21 (2002) 616-625
23. Huttner W.B., Schiebler W., Greengard P., and De Camilli P. Synapsin I (protein I), a nerve terminal-specific phosphoprotein. III. Its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation. J. Cell Biol. 96 (1983) 1374-1388
24. Janhunen S., Mielikainen P., Paldanius P., Tuominen T.K., Ahtee L., and Kaakkola S. The effect of nicotine in combination with various dopaminergic drugs on nigrostriatal dopamine in rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 371 (2005) 480-491
25. Janssens V., and Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signaling. Biochem. J. 353 (2001) 417-439
26. Kahlig K.M., and Galli A. Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine. Eur. J. Pharmacol. 479 (2003) 153-158
27. Kahlig K.M., Javitch J.A., and Galli A. Amphetamine regulation of dopamine transport. Combined measurements of transporter currents and transporter imaging support the endocytosis of an active carrier. J. Biol. Chem. 279 (2004) 8966-8975
28. Kahlig K.M., Lute B.J., Wei Y., Loland C.J., Gether U., Javitch J.A., and Galli A. Regulation of dopamine transporter trafficking by intracellular amphetamine. Mol. Phamacol. 70 (2006) 542-548
29. 3H]dopamine release from rat striatal synaptosomes and slices. J. Neurochem. 70 (1998) 1069-1076
30. Koob G.F. Neural mechanisms of drug reinforcement. Ann. N.Y. Acad. Sci. 654 (1992) 171-191
31. Krijnse-Locker J., Parton R.G., Fuller S.D., Griffiths G., and Dotti C.G. The organization of the endoplasmic reticulum and the intermediate compartment in cultured rat hippocampal neurons. Mol. Biol. Cell 6 (1995) 1315-1332
32. Ksir C., Mellor G., Hart C., and Gerhardt G.A. Nicotine enhances dopamine clearance in rat nucleus accumbens. Prog. Neuro-psychopharmacol. Biol. Psychiatry 19 (1995) 151-156
33. Lee K.H., Kim M.Y., Kim D.H., and Lee Y.S. Syntaxin 1A and receptor for activated C kinase interact with the N-terminal region of human dopamine transporter. Neurochem. Res. 29 (2004) 1405-1409
34. Little K.Y., Elmer L.W., Zhong H., Scheys J.O., and Zhang L. Cocaine induction of dopamine transporter trafficking to the plasma membrane. Mol. Pharmacol. 61 (2002) 436-445
35. Loder M.K., and Melikian H.E. The dopamine transporter constitutively internalizes and recycles in a protein kinase C-regulated manner in stably transfected PC12 cell lines. J. Biol. Chem. 278 (2003) 22168-22174
36. Melikian H.E. Neurotransmitter transporter trafficking: endocytosis, recycling, and regulation. Pharmacol. Ther. 104 (2004) 17-27
37. Melikian H.E., McDonald J.K., Gu H., Rudnick G., Moore K.R., and Blakely R.D. Human norepinephrine transporter. Biosynthetic studies using a site-directed polyclonal antibody. J. Biol. Chem. 269 (1994) 12290-12297
38. Melikian H.E., Ramamoorthy S., Tate C.G., and Blakely R.D. Inability to N-glycosylate the human norepinephrine transporter reduces protein stability, surface trafficking, and transport activity but not ligand recognition. Mol. Pharmacol. 50 (1996) 266-276
39. Middleton L.S., Cass W.A., and Dwoskin L.P. Nicotinic receptor modulation of dopamine transporter function in rat striatum and medial prefrontal cortex. J. Pharmacol. Exp. Ther. 308 (2004) 367-377
40. Nakayama H., Numakawa T., Ikeuchi T., and Hatanaka H. Nicotine-induced phosphorylation of extracellular signal-regulated protein kinase and CREB in PC12h cells. J. Neurochem. 79 (2001) 489-498
41. Pomerleau C.S., and Pomerleau O.F. Euphoriant effects of nicotine in smokers. Psychopharmacology 108 (1992) 460-465
42. Pontieri F.E., Tanda G., Orzi F., and Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 382 (1996) 255-257
43. Pristupa Z.B., McConkey F., Liu F., Man H.Y., Lee F.J., Wang Y.T., and Niznik H.B. Protein kinase-mediated bidirectional trafficking and functional regulation of the human dopamine transporter. Synapse 30 (1998) 79-87
44. Rajagopalan S., Xu Y., and Brenner M.B. Retention of unassembled components of integral membrane proteins by calnexin. Science 263 (1994) 387-390
45. Ramamoorthy S., Melikian H.E., Qian Y., and Blakely R.D. Biosynthesis, N-glycosylation, and surface trafficking of biogenic amine transporter proteins. Methods Enzymol. 296 (1998) 347-370
46. 3H]dopamine release by nicotine in rat nucleus accumbens. J. Neurochem. 49 (1987) 1449-1454
47. Salvatore M.F., Apparsundaram S., and Gerhardt G.A. Decreased plasma membrane expression of striatal dopamine transporter in aging. Neurobiol. Aging 24 (2003) 1147-1154
48. Saunders C., Ferrer J.V., Shi L., Chen J., Merrill G., Lamb M.E., Leeb-Lundberg L.M., Carvelli L., Javitch J.A., and Galli A. Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc. Natl. Acad. Sci. 97 (2000) 6850-6855
49. Smith D.A., Hoffman A.F., David D.J., Adams C.E., and Gerhardt G.A. Nicotine-evoked nitric oxide release in the rat hippocampal slice. Neurosci. Lett. 255 (1998) 127-130
50. Sorkina T., Hoover B.R., Zahniser N.R., and Sorkin A. Constitutive and protein kinase C-induced internalization of the dopamine transporter is mediated by a clathrin-dependent mechanism. Traffic 6 (2005) 157-170
51. Stolerman I.P., and Jarvis M.J. The scientific case that nicotine is addictive. Psychopharmacology 117 (1995) 2-10
52. Taubenblatt P., Dedieu J.C., Gulik-Krzywicki T., and Morel N. VAMP (synaptobrevin) is present in the plasma membrane of nerve terminals. J. Cell Sci. 112 (1999) 3559-3567
53. Torres G.E., Gainetdinov R.R., and Caron M.G. Plasma membrane monoamine transporters: structure, regulation and function. Nat. Rev., Neurosci. 4 (2003) 13-25
54. Vaughan R.A., Huff R.A., Uhl G.R., and Kuhar M.J. Protein kinase C-mediated phosphorylation and functional regulation of dopamine transporters in striatal synaptosomes. J. Biol. Chem. 272 (1997) 15541-15546
55. Vezina P., Blanc G., Glowinski J., and Tassin J.P. Nicotine and morphine differentially activate brain dopamine in prefrontocortical and subcortical terminal fields: effects of acute and repeated injections. J. Pharmacol. Exp. Ther. 261 (1992) 484-490
56. Volz T.J., and Schenk J.O. L-Arginine increases dopamine transporter activity in rat striatum via a nitric oxide synthase-dependent mechanism. Synapse 54 (2004) 173-182
57. Westfall T.C., Grant H., and Perry H. Release of dopamine and 5-hydroxytryptamine from rat striatal slices following activation of nicotinic cholinergic receptors. Gen. Pharmacol. 14 (1983) 321-325
58. Zahniser N.R., and Doolen S. Chronic and acute regulation of Na+/Cl-dependent neurotransmitter transporters: drugs, substrates, presynaptic receptors, and signaling systems. Pharmacol. Ther. 92 (2001) 21-55
59. Zahniser N.R., and Sorkin A. Rapid regulation of the dopamine transporter: role in stimulant addiction?. Neuropharmacology 47 (2004) 80-91
60. Zahniser N.R., Larson G.A., and Gerhardt G.A. In vivo dopamine clearance rate in rat striatum: regulation by extracellular dopamine concentration and dopamine transporter inhibitors. J. Pharmacol. Exp. Ther. 289 (1999) 266-277
61. Zhu J., Ayers J.T., Ghosheh O.A., Sumithran S.P., Crooks P.A., and Dwoskin L.P. N-n-Alkylnicotinium and N-n-alkylpyridinium analogs inhibit of dopamine transporter function: selectivity as nicotinic receptor antagonists. Drug Dev. Res. 60 (2003) 270-284
62. Zhu J., Apparsundaram S., Bardo M.T., and Dwoskin L.P. Environmental enrichment decreases cell surface expression of the dopamine transporter in rat medial prefrontal cortex. J. Neurochem. 93 (2005) 1434-1443